|
|
ORTHOKNOW content is posted to these pages in real time.
Monthly compilations are available in PDF form.
Quarterly Review
2Q13 Revenue: Integra LifeSciences
August 1, 2013
-
Orthopaedic sales $76.5MM, -5%
-
U.S. Extremities $33.5MM, +5%
-
U.S. Spine & Other $42.9MM, -12%
-
Orthobiologics flat due to backorders in collagen and ceramic bone void fillers; supply should return to normal by end of 3Q
-
Attributed Spine & Other decline to market softness, price pressure and execution challenges (e.g., converting ineffective distributors out/bringing in new ones); 60% of decline was private label, 40% spine
-
In 3Q, received 510(k) clearance for Titan Reverse Shoulder; limited U.S. launch occurring in 3Q with full global launch expected in 1Q14
|
|
|
